Ann: Mesoblast Update on Chronic Low Back Pain Program, page-198

What pressure or influence from SurgCentre?

They are shareholders. They have been given the same incorrect and non-functioning email address all the other shareholders have been given. They are still waiting for the “weeks” to elapse. They are peeved that they are in the red just like all the other shareholders that are in the red. I don’t believe there are different levels of shareholders.

The newly appointed board member? To soon and there’s only one - next to no influence if ever.

The only ‘power’ they have is to sell (like the rest of us shareholders). MSB has the cash and if that’s what they want then so be it. I don’t think it would be the case for about 20 different reasons.

The partnership here is where the power lies in this situation. SurgCentre strong arming the partnership is not likely - what would the “or else” be exactly?

If we assume Grunenthal is not stupid and they share the power and most likely hold the greater power than this would have to be to their benefit. How? I don’t know but whatever it is, it’s linked to the USA and FDA.

Time will tell.

Grunenthal have to be running the trials. Maybe SurgCentre would be utilised but that’s not the driver here - it’s not enough to force what has happened in this announcement.

Mysterious!

Grunenthal would have to be wanting to pick up the rights for the USA, surely.